Navigation Links
Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo
Date:2/26/2008

The marker, Apo-TRACE(TM), offers a breakthrough in advancing apoptosis-related research in a range of fields in biology and medicine

ST. LOUIS, Feb. 26 /PRNewswire-FirstCall/ -- Sigma-Aldrich(TM) (Nasdaq: SIAL) and NeuroSurvival Technologies Ltd. (NST) announced today that they have signed a licensing agreement for a leading marker, developed by NST, for molecular imaging of apoptosis in vitro and in vivo in animals. The marker, developed by NST, will be manufactured and marketed by Sigma-Aldrich under the commercial name Apo-TRACE(TM) (http://www.sigma.com/apotrace). Apo-TRACE(TM) is a member of a family of proprietary small molecules developed by NST that target apoptosis. Another molecule of the family, ApoSense(TM)-PET, is in clinical trials for imaging apoptosis in vivo in humans with PET (positron emitting tomography) and is not part of this agreement.

Apoptosis (programmed cell death) is a fundamental biological process of cell "suicide", inherent in every cell in body, and its discovery is regarded as one of the major recent revolutions in biology and medicine. Apoptosis has an important role in almost any medical disorder, and its control may hold the promise for substantial advances in medical care for a wide array of medical disorders, ranging from cancer, myocardial infarction and cerebral stroke, to neurodegenerative disorders such as Alzheimer's disease.

Respectively, extensive scientific work is continuously being performed in the field of apoptosis worldwide, involving thousands of research groups, and generating over 17,000* peer-reviewed scientific papers in 2006 alone. Apo-TRACE is a unique and novel solution to the need of researchers for imaging of apoptosis in vivo, in the living organism. As such, it may substantially contribute to advancing preclinical research in variety of fields. Upon a simple intravenous administration, Apo-TRACE selectively target
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sigma-Aldrich Announces mirPremier(TM) microRNA Isolation Kit for miRNA Purification
2. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
3. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
4. Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses
5. Researchers propose consumers buy yearly drug licenses as new way to pay for prescriptions
6. DuPont Licenses Breakthrough Automotive Coating Technology to German Paint Maker
7. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
8. Cyberonics Licenses Obesity-Related Patents
9. SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution
10. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
11. HealthTek Software Solutions Licenses First DataBanks OrderView Med Knowledge Base(TM) to Streamline Medication Selection, Management and Reconciliation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... CA (PRWEB) March 31, 2015 Dr. Poneh ... now offer patients valuable savings through new Spring specials. Dr. ... off the holiday celebration this year by taking advantage of ... , "Spring brings together friends and loved ones that ... media. We are pleased to offer solutions for a great ...
(Date:3/31/2015)... 31, 2015 A' Design Award and ... Bruker EVOQ by Daniel Dion has been announced as ... Scientific Instruments, Medical Devices and Research Equipment Design ... the creative mind behind the award winning Medical Product ... developed under the direction of Dr. Rohan Thakur and ...
(Date:3/31/2015)... 2015 According to a recent YouGov/Huffington ... Americans interviewed supported detox and abstinence, while only 19% ... methadone.(1) Although many within the healthcare community advocate for ... suggest that most Americans concur with Novus Medical ... drug use is a better approach than prescribing other ...
(Date:3/31/2015)... March 31, 2015 A team of ... polyphenol with anti-cancer properties, into mesothelioma cancer cells. Surviving ... research on its website. Click here to read ... the yellow color to the spice turmeric, has limited ... bioavailability. Biomaterials experts at Università di Napoli Federico II ...
(Date:3/31/2015)... TN (PRWEB) March 31, 2015 Dr. ... welcomes warmer temperatures and sunshine; however, it's important to be ... eye damage. Experts say more than 90 percent ... few precautions and wearing safety glasses. Dr. Shofner shares five ... this season. , 1) Yard Work. While using a lawn ...
Breaking Medicine News(10 mins):Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, is Now Offering Various Special Offers Just in Time for Spring 2Health News:Daniel Dion wins Golden in A' Medical Product Design Awards 2Health News:Novus Medical Detox Center Highlights Survey Findings: More Americans Support Detox and Rehab Over Methadone as Treatment for Heroin Addiction 2Health News:Novus Medical Detox Center Highlights Survey Findings: More Americans Support Detox and Rehab Over Methadone as Treatment for Heroin Addiction 3Health News:Novus Medical Detox Center Highlights Survey Findings: More Americans Support Detox and Rehab Over Methadone as Treatment for Heroin Addiction 4Health News:New Research Reveals Novel Delivery Method for Potential Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 3Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 4
... cholesterol and high blood pressure in people who,ve had a ... attack, according to a study to be presented as part ... Neurology,s 61st Annual Meeting in Seattle, April 25 - May ... LDL cholesterol, low HDL cholesterol, high triglycerides, and high blood ...
... -- Traumatic brain injury (TBI), a complex ... among Veterans and has been called one of the ... TBI is wide-ranging. Among its goals: shedding light on ... screening and diagnosis; developing drugs to treat brain injury ...
... April 30, 2009) A unique mother-daughter study that ... shows that percent of breast water could be linked to ... , The findings, published online today in Lancet Oncology ... more about breast density, an inheritable characteristic known to be ...
... of a novel therapy that uses magnetic pulses to ... a promising alternative to medication. , The therapy is ... were presented today (April 29, 2009) during the annual ... , In a previous randomized controlled clinical study ...
... Washing Hands, Recognizing Symptoms Key to Prevent Spread , ... attention to symptoms of illness are just some of ... the risk from the swine flu (H1N1) outbreak, the ... )"This is a serious situation that has ...
... ... 9:00 a.m. EDT, ... 1-800-814-4860, ... invites analysts and investors to participate in a briefing on Wednesday, May 6, 2009, with ...
Cached Medicine News:Health News:Controlling Cholesterol, Blood Pressure Adds Up to Prevent Stroke 2Health News:Video: Turning Hope Into Reality - Traumatic Brain Injury Research at the VA 2Health News:Mother-daughter breast density study points way to earlier cancer risk assessment 2Health News:New therapy based on magnetic stimulation shows promise for non-drug treatment for migraine 2Health News:Red Cross Urges Families and Communities to Prepare During Swine Flu Outbreak 2Health News:Red Cross Urges Families and Communities to Prepare During Swine Flu Outbreak 3Health News:Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results 2
(Date:3/30/2015)... , March 30, 2015 ... My Diabetes Emergency Plan at the 2015 @NatHurricaneCon ... to be prepared to manage your #diabetes before emergencies ... (ACE) – the charitable, educational and scientific arm of ... joined forces with Lilly Diabetes to share the ...
(Date:3/30/2015)... 30, 2015  Check-Cap Ltd. (NASDAQ: CHEK ), ... development of a preparation-free ingestible imaging capsule that utilizes ... today that its CEO, Guy Neev , will ring ... day.  Neev and Check-Cap will participate in the closing ... public offering and simultaneous private placement which raised a ...
(Date:3/30/2015)... and ORANGEBURG, N.Y., March 30, 2015  Uroplasty, ... VSCI ) shareholders have voted at the ... to approve the previously announced agreement and plan ... "We are pleased with the outcome of today,s ... both shareholder groups for approving the merger agreement," ...
Breaking Medicine Technology:Preparation Is Personal for Those with Chronic Illnesses 2Preparation Is Personal for Those with Chronic Illnesses 3Preparation Is Personal for Those with Chronic Illnesses 4Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 2Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 2Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 4
... , EAST HANOVER, N.J., Oct. 12 Novartis Pharma AG ... rights to Fanapt(TM) (iloperidone), a new oral medication ... (FDA) for the acute treatment of adults with schizophrenia. Novartis ... early 2010. , As part of the agreement with ...
... 12 Hospira, Inc. (NYSE: HSP ), a leading ... the company will present at the Credit Suisse 18th Annual ... , The presentation is scheduled to begin at 8:00 a.m. ... will be available to all interested parties through a live ...
Cached Medicine Technology:Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 2Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 3Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 4Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 5Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 6Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 7Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 8
... most powerful, comprehensive and most proven ... OfficeMate is the most widely used ... out of every three computerized eyecare ... of all your practice management needs ...
... management software for eyecare professionals- ... multi-tasking, multi-office practice management system, ... technology- Winx Pro is a ... you in effectively managing the ...
Easy-to-use and afforable practice management software. For more details, please contact First Insight....
... Working with over 2,500 ... proud to serve one ... client bases in the ... PM Ophthalmology, we are ...
Medicine Products: